Related Experiment Video
Updated: Jun 26, 2026
13:08
Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
Published on: September 9, 2011
27.5K
Calcium-mediated zoledronate loading onto carbon nanohorns
Maki Nakamura1, Yumiko Yamamoto1, Minfang Zhang2
1Nanomaterials Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Central 5, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8565, Japan. ma-ki-nakamura@aist.go.jp.
Nanoscale
|August 22, 2024
Summary
This study introduces OxCNH-Ca-ZOL, a novel nanocomposite for treating bone fragility. Despite lower ZOL content, it effectively suppresses osteoclast viability and differentiation, similar to the previous OxCNH-CaP-ZOL formulation.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Oncology
Background:
- Zoledronate (ZOL) bisphosphonate shows anti-osteoclast effects, enhanced by the OxCNH-CaP-ZOL nanocomposite for bone cancer.
- Previous OxCNH-CaP-ZOL nanocomposites contained by-products, necessitating improved formulations.
Purpose of the Study:
- To develop advanced nanocomposites lacking by-products by controlling ion availability during preparation.
- To investigate the properties and efficacy of a new ZOL-loaded nanostructure, OxCNH-Ca-ZOL.
Main Methods:
- Synthesized OxCNH-Ca-ZOL nanocomposite with ZOL loading mediated by calcium (Ca).
- Compared ZOL content, cellular uptake, and anti-osteoclastogenic effects of OxCNH-Ca-ZOL versus OxCNH-CaP-ZOL in RAW264.7 cells.
- Assessed suppression of receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclast differentiation.
Main Results:
- OxCNH-Ca-ZOL exhibited approximately half the ZOL content of OxCNH-CaP-ZOL.
- Murine macrophages (RAW264.7 cells) showed lower uptake of OxCNH-Ca-ZOL compared to OxCNH-CaP-ZOL.
- Despite reduced uptake, OxCNH-Ca-ZOL demonstrated comparable suppression of RAW264.7 cell viability and RANKL-induced osteoclast differentiation as OxCNH-CaP-ZOL, outperforming free ZOL.
Conclusions:
- The novel OxCNH-Ca-ZOL nanocomposite effectively inhibits osteoclast formation and viability, similar to the previous formulation, despite lower ZOL loading.
- Potential differences in ZOL release rates may explain the comparable efficacy of OxCNH-Ca-ZOL and OxCNH-CaP-ZOL.
- OxCNH-Ca-ZOL represents a promising therapeutic candidate for bone fragility, particularly in metastatic bone cancer contexts.
Related Concept Videos
01:31Osteoclasts in Bone Remodeling
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
01:21Skeleton and Calcium Homeostasis
Calcium is not only the most abundant mineral in bone but also the most abundant mineral in the human body. Calcium ions are needed for bone mineralization, tooth health, heart rate regulation and strength of contraction, blood coagulation, the contraction of smooth and skeletal muscle cells, and the regulation of nerve impulse conduction. The average calcium level in the blood is about 10 mg/dL. When the body cannot maintain this level, a person will experience hypo or hypercalcemia.